Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/32357
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMuriel, Javier-
dc.contributor.authorMargarit, César-
dc.contributor.authorPlanelles, Beatriz-
dc.contributor.authorSerralta, María J.-
dc.contributor.authorPuga, Carmen-
dc.contributor.authorInda, María del Mar-
dc.contributor.authorCutillas, Esperanza-
dc.contributor.authorMorales, Domingo-
dc.contributor.authorHorga, José Francisco-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-06-27T10:57:14Z-
dc.date.available2024-06-27T10:57:14Z-
dc.date.created2018-08-
dc.identifier.citationAnnals of the New York Academy Science. 2018 Aug;1425(1):82-93es_ES
dc.identifier.issn1749-6632-
dc.identifier.issn0077-8923-
dc.identifier.urihttps://hdl.handle.net/11000/32357-
dc.description.abstractScreening for opioid use disorder should be considered in chronic non-cancer pain (CNCP) patients with long-term use of opioids. The aim of our study was to assess the effectiveness of an individualized treatment plan (ITP) for prescription opioid dependence that included screening of pharmacogenetic markers. An observational prospective study was performed using prescription opioid-dependent CNCP outpatients (n = 88). Patients were divided into nonresponders, responders, or high responders according to their response to the ITP. Genotyping of OPRM1 (A118G), OPRD1 (T921C), COMT (G472A), ABCB1 (C3435T), and ARRB2 (C8622T) was performed by real-time PCR. Our ITP achieved a significant reduction of the morphine equivalent daily dose (MEDD) in 64% of responders, including 33% of high responders. Nonopioid medication or buprenorphine use was significantly higher at final versus basal visit. 118-AA OPRM1 patients required significantly lower MEDD at basal and final visits. Our ITP showed effectiveness and security in reducing MEDD in opioid-dependent patients, with good conversion to buprenorphine that was more pronounced in 118-AA OPRM1 patients.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent12es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectOPRM1es_ES
dc.subjectchronic paines_ES
dc.subjectopioides_ES
dc.subjectopioid use disorderes_ES
dc.subjectpharmacogeneticses_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::615 - Farmacología. Terapéutica. Toxicología. Radiologíaes_ES
dc.titleOPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1111/nyas.13735es_ES
Appears in Collections:
Artículos Farmacología, Pediatría y Química Orgánica


Thumbnail

View/Open:
 OPRM1 influence on and effectiveness of an individualized.pdf

371,1 kB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???